Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 5, 2008, Pages 1759-1767

  Lin, Pin Fang ^a   Nowicka Sans, Beata ^a   Terry, Brian ^a   Zhang, Sharon ^a   Wang, Chunfu ^a   Fan, Li ^a   Dicker, Ira ^a   Gali, Volodymyr ^a   Higley, Helen ^a   Parkin, Neil ^b   Tenney, Daniel ^a   Krystal, Mark ^a   Colonno, Richard ^a,c  

^a BRISTOL MYERS SQUIBB   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c Presidio Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ENTECAVIR; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; EMBRYO; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MIXED INFECTION; PRIORITY JOURNAL; PROVOCATION TEST; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS;

EID: 42949095133     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01313-07     Document Type: Article

References (24)

1. Barak, O., A. Aronheim, and Y. Shaul. 2001. HBV X protein targets HIV Tat-binding protein 1. Virology 283:110-120.
2. Bartlett, J. A., M. J. Fath, R. Demasi, A. Hermes, J. Quinn, E. Mondou, and F. Rousseau. 2006. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20:2051-2064.
3. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Chang, T. T., R. G. Gish, R. de Man, A. Gadano, J. Sollano, Y. C. Chao, A. S. Lok, K. H. Han, Z. Goodman, J. Zhu, A. Cross, D. DeHertogh, R. Wilber, R. Colonno, and D. Apelian. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354:1001-1010.
5. Cory, A. H., T. C. Owen, J. A. Barltrop, and J. G. Cory. 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3:207-212.
6. DAIDS. 1997. Virology manual for HIV laboratories. Division of AIDS, National Institute of Allergy and Infectious Diseases, U.S. Department of Health and Human Services, Washington, DC. http://www.niaid.nih.gov/daids/ vir_manual/full_vir_manual.pdf.
7. Das, K., X. Xiong, H. Yang, C. E. Westland, C. S. Gibbs, S. G. Sarafianos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:4771-4779.
8. Domaoal, R. A., M. McMahon, C. L. Thio, C. M. Bailey, J. Tirado-Rives, A. Obikhod, M. Detorio, K. L. Rapp, R. F. Siliciano, R. F. Schinazi, and K. S. Anderson. 2007. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 283:5452-5459.
9. Frost, S. D., M. Nijhuis, R. Schuurman, C. A. Boucher, and A. J. Brown. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J. Virol. 74:6262-6268.
10. Innaimo, S. F., M. Seifer, G. S. Bisacchi, D. N. Standring, R. Zahler, and R. J. Colonno. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1444-1448.
11. Johnson, V. A., and R. E. Byington. 1990. Infectivity assay (virus yield assay), p. 71-76. In A. Aldovani and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, NY.
12. Levine, S., D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer, and R. J. Colonno. 2002. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46:2525-2532.
13. Levy, V., and R. M. Grant. 2006. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin. Infect. Dis. 43:904-910.
14. Martinez, V., E. Caumes, M. Eisenhut, N. Nagot, H. Weiss, and P. Van de Perre. 2007. HSV Therapy and HIV-1 Reduction. N. Engl. J. Med. 356:2323-2324.
15. McMahon, M. A., B. L. Jilek, T. P. Brennan, L. Shen, Y. Zhou, M. Wind-Rotolo, S. Xing, S. Bhat, B. Hale, R. Hegarty, C. R. Chong, J. O. Liu, R. F. Siliciano, and C. L. Thio. 2007. The HBV drug entecavir: effects on HIV-1 replication and resistance. N. Engl. J. Med. 356:2614-2621.
16. Osborn, M. K., and A. S. Lok. 2006. Antiviral options for the treatment of chronic hepatitis B. J. Antimicrob. Chemother. 57:1030-1034.
17. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
18. Sherman, M., C. Yurdaydin, J. Sollano, M. Silva, Y. F. Liaw, J. Cianciara, A. Boron-Kaczmarska, P. Martin, Z. Goodman, R. Colonno, A. Cross, G. Denisky, B. Kreter, and R. Hindes. 2006. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130:2039-2049.
19. Soriano, V., P. Barreiro, and M. Nunez. 2006. Management of chronic hepatitis B and C in HIV-coinfected patients. J. Antimicrob. Chemother. 57:815-818.
20. Visvanathan, K., N. A. Skinner, A. J. Thompson, S. M. Riordan, V. Sozzi, R. Edwards, S. Rodgers, J. Kurtovic, J. Chang, S. Lewin, P. Desmond, and S. Locarnini. 2007. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45:102-110.
21. Wainberg, M. A., H. Salomon, Z. Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, et al. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.
22. Wainberg, M. A., J. P. Sawyer, J. S. Montaner, R. L. Murphy, D. R. Kuritzkes, and F. Raffi. 2005. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir. Ther. 10:13-28.
23. Yan, J. H., M. Bifano, S. Olsen, R. A. Smith, D. Zhang, D. M. Grasela, and F. LaCreta. 2006. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J. Clin. Pharmacol. 46:1250-1258.
24. Zhang, H., Y. Zhou, C. Alcock, T. Kiefer, D. Monie, J. Siliciano, Q. Li, P. Pham, J. Cofrancesco, D. Persaud, and R. F. Siliciano. 2004. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78:1718-1729.